NCT02994784View on ClinicalTrials.gov

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 8, 2018

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
Amyloidosis; Systemic
Interventions
DRUG

Propylene Glycol-Free Melphalan Hydrochloride

Intravenous Propylene Glycol-Free Melphalan Hydrochloride

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Spectrum Pharmaceuticals, Inc

INDUSTRY

lead

Boston Medical Center

OTHER

NCT02994784 - Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients | Biotech Hunter | Biotech Hunter